Stevenage Bioscience Catalyst

Welcome ImmuONE to SBC Seed Works! We’re pleased to welcome ImmuONE to the SBC community, as the company takes additional office space on campus alongside its existing laboratory facilities in Stevenage.

ImmuONE specialises in human-relevant respiratory toxicology, developing advanced in vitro models of the human lung and immune system to help organisations better understand ...

Welcome Synthistat to SBC! We’re delighted to welcome Synthistat to the SBC community and our Lab Hotel.

Led by CEO and Founder Zak Hassan, Co-founder and Chair Arfan Afzal, and Senior Scientific Advisor, Dr George Okafo, Synthistat is developing innovative approaches to improve the manufacture of advanced cell and gene cancer therapies and exploring new treatments for cancer...

BioRes comes to SBC! We’re delighted to welcome BioRes Ltd to the Stevenage Bioscience Catalyst community.

Founded by Gabriel Walker and Burak Özkan, BioRes is developing a next-generation biotechnology platform focused on restoring cellular function. By harnessing advances in cellular restoration, the company aims to address some of the underlying causes of age-related decli...

Vectoris Bio Check into the Lab Hotel at SBC

We’re delighted to welcome VectorisBio to the Lab Hotel at Stevenage Bioscience Catalyst.

CSO and Co Founder of Vectoris Bio Dr Shaleem Jacob

Co Founded by Dr Shaleem Jacob, CSO, VectorisBio is using artificial intelligence to develop smarter ways of purifying viral vectors, helping make t...

Ossianix Receives US$800,000 MS Society Funding Ossianix Receives Funding from the National Multiple Sclerosis Society’s Fast Forward Program to Advance Brain Penetrant Anti CD20 Therapy for Progressive MS

Stevenage, UK,  7 July 2026 

Ossianix, Inc. today announced that it has received a US$0.8 million grant from Fast Forward – the commercial...